
    
      Patients with relapsed or refractory (RR) NK and T-cell Lymphoma (NKTCL), who have received
      at least 1 prior systemic therapy, were enrolled in cohort 1. The study design for cohort 1
      was a single arm phase II 2-stage design, to explore monotherapy with the PD-1 antibody
      pembrolizumab (or MK-3475) given intravenously at a fixed dose of 200mg every 3 weeks for up
      to 36 cycles. Enrollment to this cohort has been completed.
    
  